Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03175861
Other study ID # MUMOFRAT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 14, 2017
Est. completion date June 2020

Study information

Verified date October 2018
Source University Hospital, Brest
Contact Ulrike Schick, Doctor
Phone 0298223398
Email ulrike.schick@chu-brest.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Identify 18-Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) parameters predictive of tumor response and local control


Description:

The identification of robust prognostic and predictive markers could allow the individualization of pulmonary stereotactic radiotherapy treatments and the selection of patients at high risk of relapse, who could then benefit from a dose escalation in order to increase the chances of local control .

Beyond the pulmonary RTS (Radiotherapy in stereotactic condition), this study will aim to generate one or more models of multi-scale response to hypofractionated irradiation from biomarkers (biological or images) extracted from preclinical or clinical literature data and to allow simulations of Various modified fractionation irradiation schemes, potentially leading to new regimens that reduce side effects and increase therapeutic efficacy.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2020
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age> 18 years

- Performance Index WHO (World Health Organization) = 2

- Bronchopulmonary carcinoma not in small cells proved histologically or cytologically (epidermoid, adenocarcinoma, or large cell carcinoma).

- Tumor classified T1 - T2 (Tumor=1-2) N0 (Node=0) M0 (Metastasis=0) and diameter = 5 cm or Tumor classified T3 (=5cm) N0M0 of the chest wall

- Tumor located more than 2 cm from the trachea and bronchus stem and more than 1.5 cm from the organs at risk

- Medically inoperable or refusing surgery

- Indication of stereotactic radiotherapy validated in multidisciplinary consultation meeting

- Formulation of consent

Exclusion Criteria:

- Age <18 years.

- History of pulmonary irradiation

- Pulmonary surgery of the tumor

- Different histology of non-small cell carcinoma

- Patient with a T2 or T3> 5 cm tumor or patients with a T3 tumor invading a structure other than the chest wall

- Patient with a tumor within 2 cm of the trachea and bronchus stem and within 1.5 cm of the organs at risk in the proximal area of the no fly zone (defined as a volume Located 2 cm in all directions of the proximal bronchial tree - Pulmonary metastases

- Declared pregnancy, breast-feeding

- Refusal to use effective contraception

- Against indication to the realization of the PET to the 18FDG (18-fluorodeoxyglucose)(uncontrolled diabetes)

- Refusal or inability to consent to participate in the study.

- Estimated life expectancy <2 months in the absence of treatment

- Other invasive tumors diagnosed in the previous 2 years, with the exception of non-melanocytic cutaneous carcinomas.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stereotactic radiotherapy
The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent. Then the patient will receive his treatment by conventional stereotactic radiotherapy

Locations

Country Name City State
France CHRU de Brest Brest
France Centre Eugène Marquis Rennes
France Institut de Cancérologie de l'Ouest Saint-Herblain
France Clinique d'Oncologie et Radiothérapie Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Kinetics of PET-CT parameters : standardized uptake value (SUV) max SUV max will be measured before and after stereotactic irradiation. 2 years
Primary Tumor metabolic response Tumor metabolic response, as assessed on 18F-FDG PET-CT at 6 months of end of radiotherapy 2 years
Primary Local control Local control defined by the absence of progression in the irradiated area 2 years
Primary Kinetics of PET-CT parameters : metabolic tumor volume Metabolic tumor volume (MTV) will be measured before and after stereotactic irradiation. 2 years
Primary Kinetics of PET-CT parameters : texture parameters :quantitative extraction of images by specific software The first-order form parameters and statistical parameters, the second order (based on the matrix of co-occurrence of the grey levels and the matrix of differences of grey levels) and of the third order (based on the matrices of alignment of the grey levels and the matrices of sizes of zones) will be studied. 2 years
Secondary Kinetics of serum markers The kinectic will be measured 2 years
Secondary Predictive power of serum markers for tumor response and local control This predictive power will be measured 2 years
Secondary Predictive power of metabolic imaging parameters for tumor response and local control Predictive power of metabolic imaging parameters for tumor response and local control This predictive power will be measured 2 years
Secondary Correlation between these parameters The correlation will be measured 2 years
Secondary Survival in disease The survival in desease will be observed 2 years
Secondary Survival without metastasis at a distance The survival without metastasis will be observed 2 years
Secondary Radiation-induced toxicity The radiation-induced toxicity will be observed 2 years
See also
  Status Clinical Trial Phase
Completed NCT01439152 - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting NCT06015009 - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers N/A
Active, not recruiting NCT03298100 - Risk Scoring Model for Endometrial Cancer
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Not yet recruiting NCT04324320 - Psychological Distress in Outpatient Oncological Rehabilitation
Completed NCT00588289 - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA N/A
Recruiting NCT06222801 - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting NCT03831633 - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients Phase 4
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting NCT05712174 - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer Phase 2
Recruiting NCT03832062 - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed NCT03988777 - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting NCT06031233 - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Phase 4
Enrolling by invitation NCT04019119 - Digital Intervention for the Modification of Lifestyles (iGame) N/A
Not yet recruiting NCT05926362 - Capillary-Venous Paired Data Collection
Recruiting NCT05686213 - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial Phase 2
Recruiting NCT05510856 - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients Phase 4
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors